Topics

Drug Research

Lilly Alzheimer's drug shows benefit in those treated early

Lilly Alzheimer's drug shows benefit in those treated early

Patients who started Eli Lilly & Co.'s experimental Alzheimer's drug earlier in their disease's progression consistently did better on follow-up memory and thinking tests than those who waited to be treated, a study found. The result shows that Lilly's drug, called solanezumab, has the potential to slow the course of the memory-robbing disorder, researchers said. The study was released Wednesday at the Alzheimer's Association International Conference in Washington. An extension of two major trials, it also advances Lilly's bid to be the first drugmaker with a treatment that affects the disease itself. "To be fair, solanezumab doesn't stop the...

Loading
80°